milrinone lactate

Apo-Milrinone (CA)

Pharmacologic class: Bipyridine phosphodiesterase inhibitor

Therapeutic class: Inotropic

Pregnancy risk category C

Action

Increases cellular levels of cyclic adenosine monophosphate, causing inotropic action that relaxes vascular smooth muscle and increases myocardial contractility

Availability

Injection: 1 mg/ml in 10-, 20-, and 50-ml vials

Injection (premixed): 200 mcg/ml in dextrose 5% in water (D₅W)

Indications and dosages

➣ Heart failure

Adults: Initially, 50 mcg/kg I.V. bolus given slowly over 10 minutes, followed by continuous I.V. infusion of 0.375 to 0.75 mcg/kg/minute. Don't exceed total daily dosage of 1.13 mg/kg.

Dosage adjustment

• Renal impairment

Contraindications

• Hypersensitivity to drug

Precautions

Use cautiously in:

• atrial flutter or fibrillation, supraventricular and ventricular arrhythmias, renal impairment, electrolyte abnormalities, decreased blood pressure, severe aortic or pulmonic valvular disease, acute phase of myocardial infarction (not recommended), electrolyte abnormalities, abnormal blood digoxin level

• elderly patients

• pregnant or breastfeeding patients

• children (safety and efficacy not established).

Administration

• Dilute 1 mg/ml solution with half-normal saline solution, normal saline solution, or D₅W per manufacturer's instructions.

See Don't administer through same I.V. line as furosemide or torsemide (precipitate will form).

• Deliver I.V. slowly over 10 minutes.

• Expect to titrate infusion rate depending on response.

Adverse reactions

CNS: headache

CV: hypotension, chest pain, angina, ventricular or supraventricular arrhythmias, ventricular tachycardia or fibrillation

Interactions

None significant

Patient monitoring

• Monitor vital signs and ECG. Watch closely for ventricular arrhythmias, sustained tachycardia, and fibrillation.

• Assess cardiovascular status closely. Stay alert for complaints of chest pain.

See Stop drug and contact prescriber immediately if patient's systolic pressure drops 30 mm Hg or more.

Patient teaching

• Instruct patient to change position slowly, to avoid light-headedness or dizziness from hypotension.

• As appropriate, review all other significant and life-threatening adverse reactions.

单词	milrinone lactate
释义	milrinone lactate milrinone lactate Apo-Milrinone (CA) *Pharmacologic class:* Bipyridine phosphodiesterase inhibitor *Therapeutic class:* Inotropic *Pregnancy risk category C* Action Increases cellular levels of cyclic adenosine monophosphate, causing inotropic action that relaxes vascular smooth muscle and increases myocardial contractility Availability Injection: 1 mg/ml in 10-, 20-, and 50-ml vials Injection (premixed): 200 mcg/ml in dextrose 5% in water (D₅W) Indications and dosages ➣ Heart failure Adults: Initially, 50 mcg/kg I.V. bolus given slowly over 10 minutes, followed by continuous I.V. infusion of 0.375 to 0.75 mcg/kg/minute. Don't exceed total daily dosage of 1.13 mg/kg. Dosage adjustment • Renal impairment Contraindications • Hypersensitivity to drug Precautions Use cautiously in: • atrial flutter or fibrillation, supraventricular and ventricular arrhythmias, renal impairment, electrolyte abnormalities, decreased blood pressure, severe aortic or pulmonic valvular disease, acute phase of myocardial infarction (not recommended), electrolyte abnormalities, abnormal blood digoxin level • elderly patients • pregnant or breastfeeding patients • children (safety and efficacy not established). Administration • Dilute 1 mg/ml solution with half-normal saline solution, normal saline solution, or D₅W per manufacturer's instructions. See Don't administer through same I.V. line as furosemide or torsemide (precipitate will form). • Deliver I.V. slowly over 10 minutes. • Expect to titrate infusion rate depending on response. Adverse reactions CNS: headache CV: hypotension, chest pain, angina, ventricular or supraventricular arrhythmias, ventricular tachycardia or fibrillation Interactions None significant Patient monitoring • Monitor vital signs and ECG. Watch closely for ventricular arrhythmias, sustained tachycardia, and fibrillation. • Assess cardiovascular status closely. Stay alert for complaints of chest pain. See Stop drug and contact prescriber immediately if patient's systolic pressure drops 30 mm Hg or more. Patient teaching • Instruct patient to change position slowly, to avoid light-headedness or dizziness from hypotension. • As appropriate, review all other significant and life-threatening adverse reactions.
随便看	violet-blue violet catastrophe violet (character) violet-colored violet-coloured violet (comics) violet creeper society of auburn inc violet-ear violet family violet-flowered violet-flowered petunia violet layer violet-like violetly violet metals and chemicals violet-pink thetas theta-secretase theta-secretase2 beta-site app cleaving enzyme 2 theta series theta-series the taskmaster the tasmanian tiger (thylacinus cynocephalus) theta-theta the tatler